Matinas BioPharma (NYSEAMERICAN:MTNB) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Matinas BioPharma and Karyopharm Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Matinas BioPharma | 0 | 0 | 4 | 0 | 3.00 |
| Karyopharm Therapeutics | 0 | 1 | 8 | 0 | 2.89 |
Matinas BioPharma currently has a consensus target price of $3.3750, indicating a potential upside of 234.16%. Karyopharm Therapeutics has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Given Matinas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Matinas BioPharma is more favorable than Karyopharm Therapeutics.
Valuation & Earnings
This table compares Matinas BioPharma and Karyopharm Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Matinas BioPharma | $90,000.00 | 2,292.43 | $-17,370,000.00 | ($0.13) | -7.77 |
| Karyopharm Therapeutics | $40.89 million | 18.29 | $-199,590,000.00 | ($3.22) | -3.11 |
Matinas BioPharma has higher earnings, but lower revenue than Karyopharm Therapeutics. Matinas BioPharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Matinas BioPharma and Karyopharm Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Matinas BioPharma | N/A | -37.07% | -31.41% |
| Karyopharm Therapeutics | -221.23% | -187.66% | -56.42% |
Institutional and Insider Ownership
22.8% of Matinas BioPharma shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 7.8% of Matinas BioPharma shares are held by insiders. Comparatively, 13.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Matinas BioPharma has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
Summary
Matinas BioPharma beats Karyopharm Therapeutics on 9 of the 14 factors compared between the two stocks.
